PRESS OFFICE
LISTING
Homenewsabout usContact UsWebsite
Welcome to the
Cipla Press Office
Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support.
Follow us:
 

Latest news

Understanding depression and related symptoms key to suicide prevention in SAAccording to the World Health Organisation (WHO), South Africa has the sixth highest rate of suicide in Africa, with the data revealing that approximately 11.6 of every 100,000 people in the country completing suicide1. It is commonly accepted that the majority of suicides and suicide attempts occur among individuals who suffer from undiagnosed and untreated depression, with the WHO estimating that more than 300 million people are affected by depression worldwide2. 18 Sep 2018 Read more

Cipla's new triple-combination antiretroviral drug approvedThe South African Health Products Regulatory Authority (SAHPRA) has approved Cipla's latest first-line triple-combination antiretroviral (ARV) treatment for HIV. The new combination medicine commonly referred to as TLD, is a combination of tenofovir (TDF), lamivudine (3TC) and dolutegravir (DTG). 12 Sep 2018 Read more

Cipla South Africa grows national footprint with Mirren acquisitionCipla Medpro South Africa (Pty) Limited ("Cipla Medpro"), wholly owned subsidiary of Cipla Limited, India ("Cipla"), and South Africa's fourth-largest pharmaceutical company in the private sector, has announced its plans to acquire a 100% stake in Mirren (Pty) Limited ("Mirren"). Mirren is a South African over-the-counter (OTC) pharmaceutical manufacturer and distributor, which has been in operation for 35 years. The transaction is subject to the approval by the Competition Commission of South Africa. 8 Aug 2018 Read more

South Africa's first biosimilar oncology drug authorised for useCipla, South Africa's third-largest pharmaceutical manufacturer, in collaboration with Teva Pharmaceutical Industries Ltd, has announced the launch of the country's first biosimilar for the oncology and haematology markets. 3 Aug 2018 Read more


More news...

Contact Cipla

Email:
Tel: +27 21 943 4200
Customer Care: 080 222 6662
Website: www.cipla.co.za